
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera is positioned for strong growth due to their key product offerings and expanding global reach, as evidenced by their PMDA approval and contracts with biopharmaceutical companies. The launch of their new rare disease testing product and strong revenue growth further solidify their positive outlook, leading analysts to rate the company as Outperform. Additionally, the company's success has been attributed to their strong leadership, innovative technology, and ability to identify important factors for growth.
Bears say
Natera is a leading diagnostics company in the rapidly growing molecular residual disease (MRD) space, with a market share of over 90%. However, the company's current valuation is significantly overhyped and overvalued, making it vulnerable to potential setbacks in its growth prospects. Moreover, the MRD market presents significant competition risks, as more and more major diagnostics companies enter the space, potentially challenging Natera's leadership position. Additionally, while the company has a strong pipeline of potential catalysts in the near future, including regulatory approvals and potential expansions into new markets, there is no guarantee that these will translate into significant revenue growth in the long term. Ultimately, the lofty premium at which Natera's stock is currently trading and the potential challenges it faces in sustaining its growth trajectory make it a risky bet for investors.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares